From subscription to donation to Schedule K-1 — the structure that turns a charitable gift of hereditary cancer risk assessment into an allocable deduction for Members.
Recombinant Diagnostics LLC is a Delaware limited liability company managed by Recombinant MGMT, LLC. It is organized to expand access to hereditary cancer risk assessment by donating Panels to §501(c)(3) public charities, and to allocate the resulting charitable-contribution deduction to its Class A Members.
Class A Units are offered at $50,000 per Unit to verified accredited investors under Rule 506(c) of Regulation D, through the Company’s Private Placement Memorandum and definitive Subscription Agreement.
The Company donates Panels to qualifying §501(c)(3) public charities. A qualified appraisal supports the charitable-deduction value, and each Member receives the substantiation the Code requires, including a Schedule K-1.
Subscription capital is applied on an 80 / 20 basis per Unit — the substantial majority to acquiring the Panels that are donated, with the balance to program administration.
Applied to acquiring the unitized hereditary cancer risk-assessment Panels the Company donates to qualifying public charities.
Applied to program administration and the costs of operating the offering and the charitable program.
The Company may maintain an Audit Defense Reserve of up to $12,500,000 to support Members in connection with the charitable deductions. The Reserve offers no guarantee of outcomes and is not insurance.
A qualified appraisal is obtained to support the charitable-deduction value under §170(f)(11) and the applicable Treasury Regulations. The appraisal may be completed as late as prior to the Company’s filing of its applicable tax return.
The final closing to new subscribers. After this date, no new subscriptions are accepted.
The Panels are donated to qualifying §501(c)(3) public charities.
Redemptions, where applicable, are processed within 30 business days and no later than this date.
The Private Placement Memorandum, Operating Agreement, and Subscription Agreement govern in all respects. Confirm your accredited status to begin review.
Accredited investor access →